US stock futures muted as rate cut bets wane ahead of Jackson Hole
Introduction & Market Context
Hims & Hers Health Inc (NYSE:HIMS) unveiled ambitious long-term growth plans in its May 2025 investor presentation, setting a target of at least $6.5 billion in revenue by 2030. The telehealth company, which recently reported 111% year-over-year revenue growth for Q1 2025, is expanding beyond its core offerings while deepening its personalization capabilities.
The company’s stock, trading at $41.88 as of May 6, has experienced significant volatility over the past year, with a 52-week range of $11.64 to $72.98. Despite strong revenue performance, shares fell 3.8% following the recent earnings report that showed an EPS miss of $0.20 versus an expected $0.23.
Executive Summary
Hims & Hers is positioning itself as a comprehensive personalized healthcare platform, reaching over 100 million potential consumers across various specialties. The company’s mission centers on helping "the world feel great through the power of better health" by democratizing access to high-quality healthcare solutions.
As shown in the following mission statement slide:
The company’s strategy leverages technology to deliver personalized healthcare solutions across multiple specialties, with 60% of subscribers already using personalized products. Its leadership team, led by CEO and Co-Founder Andrew Dudum, brings experience from disruptive companies including Uber (NYSE:UBER), Amazon (NASDAQ:AMZN), Google (NASDAQ:GOOGL), and Tesla (NASDAQ:TSLA).
Strategic Initiatives
Hims & Hers is expanding beyond its established categories of Sexual Health, Dermatology, Mental Health, and Weight Loss to launch new specialties in 2025, including Testosterone and Menopause support. Future expansion plans include Longevity, Sleep, and Preventative Medicine.
The following slide illustrates the company’s reach across specialties:
The company’s platform evolution focuses on three key areas: awareness and on-demand access, exceptional service and convenience, and data-informed personalization. This approach has enabled Hims & Hers to develop increasingly precise offerings tailored to individual needs.
The platform evolution is depicted in this slide:
Strategic partnerships with industry leaders remain central to the company’s growth strategy. Notably, Hims & Hers highlighted its long-term collaboration with Novo Nordisk (NYSE:NVO), which provides access to weight loss medications like Wegovy. Other key partnerships include Ochsner, Mount Sinai, and the American College of Cardiology.
The value proposition strengthens with each new subscriber, creating a virtuous cycle of trust, technology advancement, and personalized solutions:
Product Portfolio Expansion
Hims & Hers is rapidly expanding its product portfolio with innovative solutions across multiple categories. The company has introduced differentiated form factors like Hard Mints, personalized dosages for weight loss treatments, and multi-condition offerings that address several health concerns simultaneously.
The company’s innovative solutions are showcased in this slide:
In the weight loss category, Hims & Hers offers a comprehensive range of options including Wegovy through NovoCare, Liraglutide, oral weight loss medications, and personalized Semaglutide dosages. This diversified approach allows the company to address varying subscriber profiles and BMI ranges.
The weight loss offerings are illustrated here:
Detailed Financial Analysis
Hims & Hers reported impressive financial results for Q1 2025, with revenue reaching $586 million, a 111% increase year-over-year and significantly exceeding the forecast of $538.9 million. However, the company’s EPS of $0.20 fell short of the expected $0.23, leading to the post-earnings stock decline.
The company’s subscriber base grew to nearly 2.4 million, a 38% increase year-over-year. Adjusted EBITDA nearly tripled to $91 million, while marketing spend improved to 39% of revenue. Free cash flow reached $50 million, with cash and short-term investments totaling $323 million.
For Q2 2025, Hims & Hers provided revenue guidance of $530-$550 million, representing 68-74% year-over-year growth. Full-year 2025 revenue is projected at $2.3-$2.4 billion.
Forward-Looking Statements
The most significant forward-looking element of the presentation was the announcement of new 2030 financial targets. Hims & Hers aims to achieve at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, highlighting the company’s confidence in its long-term growth strategy.
These ambitious targets are displayed in the following slide:
The company’s long-term roadmap focuses on five key levers: deepening personalization, expansion into new emotionally resonant specialties, elevated follow-up care, global expansion, and strategic partnerships to expand the ecosystem.
During the recent earnings call, CEO Andrew Dudum emphasized the company’s commitment to personalized healthcare, stating, "We’re delivering on our long-held vision, health care that’s convenient, affordable, transparent and deeply personalized." CFO Yemi Kubei added, "Consumers continue to turn to us as a solution for a better and more precise health care experience."
While the presentation paints an optimistic picture of Hims & Hers’ future, investors should note the challenges reflected in the recent EPS miss and subsequent stock decline. The company’s high marketing spend, though improving, remains a significant cost factor, and expansion into new markets carries execution risks. Nevertheless, the strong revenue growth and strategic initiatives position Hims & Hers as a potentially disruptive force in the personalized healthcare space.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.